23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process. 23andMe was set to sell itself in bankruptcy to Regeneron before former CEO Anne Wojcicki bid $305 million after the auction ended through her recently founded nonprofit TTAM Research Institute. Wojcicki’s bid dwarfs her previous offer to acquire the company for $40 million just ahead of its March bankruptcy filing.
Read the full article: 23andMe’s Former CEO Pushes Purchase Price Nearly $50M Higher //
Source: https://www.wsj.com/articles/23andmes-former-ceo-pushes-purchase-price-nearly-50-million-higher-7ec98421